Clinical Trials Logo

Metastatic Osteosarcoma clinical trials

View clinical trials related to Metastatic Osteosarcoma.

Filter by:

NCT ID: NCT01016015 Completed - Clinical trials for Recurrent Osteosarcoma

Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma

Start date: November 2009
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well temsirolimus and cixutumumab works in treating patients with locally advanced, metastatic, or recurrent soft tissue sarcoma or bone sarcoma. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cixutumumab, can block tumor growth by blocking the ability of tumor cells to grow and spread. Giving temsirolimus with cixutumumab may be an effective treatment for soft tissue or bone sarcoma.

NCT ID: NCT00954473 Completed - Clinical trials for Recurrent Osteosarcoma

Study of Blood Samples From Patients With Osteosarcoma

Start date: January 2009
Phase: N/A
Study type: Observational

This research trial studies blood samples from patients with osteosarcoma. Studying the genes found in samples of blood from patients with osteosarcoma may help doctors identify biomarkers related to the disease.

NCT ID: NCT00330421 Completed - Clinical trials for Recurrent Osteosarcoma

Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)

Start date: June 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well sorafenib works in treating patients with soft tissue sarcoma. Sorafenib may stop the growth of soft tissue sarcoma by blocking blood flow to the tumor and blocking some of the enzymes needed for tumor cell growth

NCT ID: NCT00134030 Completed - Clinical trials for Metastatic Osteosarcoma

Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

EURAMOS-1
Start date: November 14, 2005
Phase: Phase 3
Study type: Interventional

This randomized phase III trial is studying combination chemotherapy followed by surgery and two different combination chemotherapy regimens with or without PEG-interferon alfa-2b to compare how well they work in treating patients with osteosarcoma. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Biological therapies, such as PEG-interferon alfa-2b, may interfere with the growth of tumor cells. Giving combination chemotherapy before surgery may shrink the tumor so it can be removed. Giving combination chemotherapy together with PEG-interferon alfa-2b after surgery may kill any remaining tumor cells. It is not yet known whether giving combination therapy together with PEG-interferon alfa-2b is more effective than two different combination chemotherapy regimens alone after surgery in treating osteosarcoma.

NCT ID: NCT00093821 Completed - Clinical trials for Recurrent Childhood Acute Lymphoblastic Leukemia

Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors

Start date: September 2004
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of tanespimycin in treating young patients with recurrent or refractory leukemia or selected solid tumors. Drugs used in chemotherapy, such as tanespimycin, work in different ways to stop cancer cells from dividing so they stop growing or die.

NCT ID: NCT00023998 Completed - Clinical trials for Metastatic Osteosarcoma

Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma

Start date: July 2001
Phase: Phase 2
Study type: Interventional

Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and kill them without harming normal cells. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. Phase II trial to study the effectiveness of chemotherapy with or without trastuzumab in treating patients who have metastatic osteosarcoma

NCT ID: NCT00004241 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma

Start date: October 1999
Phase: Phase 1
Study type: Interventional

Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in treating patients with advanced epithelial cancer, malignant lymphoma, or sarcoma